JAC Advance Access originally published online on August 25, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy 2004 54(4):798-802; doi:10.1093/jac/dkh409
JAC vol.54 no.4 © The British Society for Antimicrobial Chemotherapy 2004; all rights reserved
Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case–control study
1 Infectious Diseases Department, Dron Hospital, 135 rue du Président Coty, 59200 Tourcoing; 2 Department of Orthopaedic Surgery, Faculty of Lille, Lille; 3 Department of Orthopaedic Surgery, Dron Hospital, Tourcoing; 4 Clinical Microbiology Laboratory, Dron Hospital, Tourcoing, France
* Corresponding author. Tel: +33-320-694-591; Fax: +33-320-694-589; Email: esenneville{at}ch-tourcoing.fr
Objectives: The intrinsic properties of the new antibiotic linezolid make it an attractive candidate for the treatment of chronic osteomyelitis. However, data regarding the tolerance of long-term linezolid administration are still lacking.
Methods: The medical charts of patients given linezolid for >4 weeks were retrospectively analysed, especially their haematology. In a case–control study, we compared the respective characteristics of patients who developed anaemia during linezolid therapy and those who did not.
Results: Forty-five adults with chronic osteomyelitis received 600 mg linezolid intravenously twice daily for 7 days, and then orally, for a mean total duration of 15.9 weeks (range, 6–36). Anaemia episodes requiring blood transfusion occurred in 13/45 patients (28.9%). Median time from treatment initiation to anaemia onset was 7.4 weeks (range, 4–16). Anaemia was significantly associated with premature linezolid therapy cessation (P=0.0012). No linezolid-related thrombocytopenia was observed. By univariate analysis, four variables were associated with the occurrence of anaemia: age >58 years, alcohol abuse, diabetes mellitus and low haemoglobin before linezolid treatment. Logistic regression analysis revealed two independent risk factors for anaemia: age >58 years (OR = 20.5, 95% CI 0.69–599; P=0.0001) and pre-treatment haemoglobin <10.5 g/dL (OR = 16.49, 95% CI 1.06–255; P=0.04).
Conclusions: Profound anaemia may occur in adult patients with chronic osteomyelitis on prolonged linezolid therapy, and often necessitates linezolid cessation. These patients are likely to be aged >58 years and to have low pre-treatment haemoglobin. The results for the present series might help physicians to identify patients who should not be given long-term linezolid treatment for chronic osteomyelitis.
Keywords: oxazolidinones , toxicity , myelosuppression
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. A. Seaton Daptomycin: rationale and role in the management of skin and soft tissue infections J. Antimicrob. Chemother., November 1, 2008; 62(suppl_3): iii15 - iii23. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Youssef, R. Hachem, R. F. Chemaly, J. Adachi, J. Ying, K. Rolston, and I. Raad The role of vitamin B6 in the prevention of haematological toxic effects of linezolid in patients with cancer J. Antimicrob. Chemother., February 1, 2008; 61(2): 421 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Soriano, M. Ortega, S. Garcia, G. Penarroja, A. Bove, M. Marcos, J. C. Martinez, J. A. Martinez, and J. Mensa Comparative Study of the Effects of Pyridoxine, Rifampin, and Renal Function on Hematological Adverse Events Induced by Linezolid Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2559 - 2563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Grau, J. A. Morales-Molina, J. Mateu-de Antonio, M. Marin-Casino, and F. Alvarez-Lerma Linezolid: low pre-treatment platelet values could increase the risk of thrombocytopenia J. Antimicrob. Chemother., August 1, 2005; 56(2): 440 - 441. [Full Text] [PDF]
|
|